Turning silos into a usable network

Drug development, evidence generation and precision medicine all depend on one thing: reliable data that can be compared, traced and trusted. In practice, that data sits in many places, under different rules, in different formats, and often behind privacy constraints that differ across countries. This lack of standardization and harmonization extends research timelines, adds complexity, and creates gaps in the data used for critical decision-making.

BC Platforms tackles this challenge with a simple principle: keep sensitive data where it belongs and bring the analysis to the data. Its federated Trusted Research Environments (TREs) allows hospitals, biobanks and other data holders to stay in control, while enabling researchers to work across multiple sources in a highly secure and governed manner. For customers, the point is not simply access, but confidence that the work is compliant and auditable, even when datasets span institutions and jurisdictions.

This is where BC Platforms’ European and Asian footprint matters. Many large players built their scale in the US, where centralised models are more common. In Europe, privacy-by-design is not a nice-to-have. It is a market requirement. By leaning into that constraint, BC Platforms has built a position in markets where regulation is an operational reality, not a future roadmap item.

From bespoke projects to repeatable products

BC Platforms has been around long enough to see several waves in life sciences data. What has changed is the market’s expectation of speed and standardisation. Pharma teams want to start small, prove value quickly and scale. They also want multimodal data, including clinical, genomic and imaging, and they want it in an environment that stands up to regulatory scrutiny.

That demand is pushing BC Platforms to develop new products and capabilities that address these needs. Its portfolio has been consolidated around a small set of core products that leverage AI, covering secure analytics environments, imaging workflows and data integration, alongside curated datasets and expert services where needed. The transition is strategically straightforward, but operationally demanding. Enterprise customers do not switch buying habits overnight, and long sales cycles are the norm. The task is to standardise delivery without losing the depth of insight that made the company valuable in the first place.

BC Platforms is handling this shift by tightening the boundary between platform and service. Core capabilities are being packaged into clearer, reusable building blocks that can be deployed more consistently across customers, while specialist services focus on the parts that genuinely vary, such as local governance, integration into existing hospital workflows, and stakeholder alignment. In parallel, the company is sharpening how it sells and delivers, prioritising use cases that can be repeated, reducing custom one-offs, and aligning commercial effort with product maturity. The result is a model that can scale without compromising the trust that regulated buyers demand.

BC Platforms is making real-world health data usable across borders